Product Comparison


 
Novartis 00078043561
Dr. Reddy's Laboratories 55111068852
Dr. Reddy's Laboratories 55111068507
Amgen Inc 55513073001
Amgen Inc 55513071001
McKesson # 625900 835520 835519 742959 729015
Description Reclast® Zoledronic Acid 5 mg / 100 mL Ready to Use Intravenous Injection Infusion Bottle 100 mL Zoledronic Acid 5 mg / 100 mL Ready to Use Intravenous Injection Infusion Bottle 100 mL Zoledronic Acid 4 mg / 5 mL Concentrate Intravenous Injection Single Use Vial 5 mL Xgeva® Denosumab 120 mg Subcutaneous Injection Single Dose Vial 1.7 mL Prolia® Denosumab, Preservative Free 60 mg / mL Subcutaneous Injection Prefilled Syringe 1 mL
Manufacturer # 0007804356155111068852551110685075551307300155513071001
Brand Reclast®  Xgeva®Prolia®
Manufacturer NovartisDr. Reddy's LaboratoriesDr. Reddy's LaboratoriesAmgen IncAmgen Inc
Invoice RECLAST, BTL INF 5MG/100ML 100MLZOLEDRONIC ACID, SDV 5MG 100MLZOLEDRONIC ACID, SDV 0.8MG/ML 5MLXGEVA, SDV PF 120MG/1.7ML 1.7MLPROLIA, SYR 60MG/ML 1M
    Log In to Order   Log In to Order   Log In to Order   Log In to Order   Log In to Order

Comparison

Alternate Manufacturer Number 17666662017226201723416114411925965
Container Type Infusion BottleInfusion BottleSingle Use VialSingle Dose VialPrefilled Syringe
Country of Origin UnknownUnknownUnknownUnknownGermany
Generic Drug Code 2502625026194762926128656
Generic Drug Name Zoledronic AcidZoledronic AcidZoledronic AcidDenosumabDenosumab, Preservative Free
NDC Number 00078-0435-6155111-0688-5255111-0685-0755513-0730-0155513-0710-01
Product Dating McKesson Acceptable Dating: we will ship >= 90 daysMcKesson Acceptable Dating: we will ship >= 90 daysMcKesson Acceptable Dating: we will ship >= 90 daysMcKesson Acceptable Dating: we will ship >= 180 daysMcKesson Acceptable Dating: we will ship >= 180 days
Storage Requirements Requires RefrigerationRequires Refrigeration
Strength 5 mg / 100 mL Ready to Use5 mg / 100 mL Ready to Use4 mg / 5 mL Concentrate120 mg60 mg / mL
Type IntravenousIntravenousIntravenousSubcutaneousSubcutaneous
UNSPSC Code 5118241551182415511824155118242851182428
User Adult
Volume 100 mL100 mL5 mL1.7 mL1 mL
Application Bone Resorption InhibitorBone Resorption InhibitorBone Resorption InhibitorBone Resorption InhibitorBone Resorption Inhibitor
Dosage Form InjectionInjectionInjectionInjectionInjection
Features and Benefits
  • Store at 25 degrees Celsius (77 degrees Fahrenheit); excursions permitted to 15 - 30 degrees Celsius (59 - 86 degrees Fahrenheit)
  • Reclast® is given as an infusion into a vein by a nurse or a doctor, and the infusion time must not be less than 15 minutes
  • Infusion solution is ready to use with Zoledronic Acid, Mannitol and Water
  • If refrigerated, allow the refrigerated solution to reach room temperature before administration
  • After opening the solution, it is stable for 24 hours at 2 - 8 degrees Celsius (36 - 46 degrees Fahrenheit)
  • Ready-to-use formulation
  • Zoledronic acid injection is a bisphosphonate indicated for the treatment of: Hypercalcemia of malignancy, multiple myeloma and bone metastases from solid tumors
  • The zoledronic acid injection infusion time must not be less than 15 minutes given over a constant infusion rate
  • Zoledronic acid injection must not be mixed with calcium or other divalent cation-containing infusion solutions, such as Lactated Ringer’s solution, and should be administered as a single intravenous solution in a line separate from all other drugs
  • Infusion bottle with built-in plastic hanger
  • One bottle with 100 mL solution contains 5.330 mg of zoledronic acid monohydrate, equivalent to 5 mg zoledronic acid on an anhydrous basis
  • Inactive Ingredients: 4950 mg of mannitol, USP; and 30 mg of sodium citrate, USP
  • Zoledronic acid injection must not be mixed with calcium or other divalent cation-containing infusion solutions, such as Lactated Ringer’s solution, and should be administered as a single intravenous solution in a line separate from all other drugs
  • Zoledronic acid injection is a bisphosphonate indicated for the treatment of: Hypercalcemia of malignancy, multiple myeloma and bone metastases from solid tumors
  • Zoledronic acid injection must not be mixed with calcium or other divalent cation-containing infusion solutions, such as Lactated Ringer’s solution, and should be administered as a single intravenous solution in a line separate from all other drugs
  • Vials of zoledronic acid injection concentrate for infusion contain overfill allowing for the withdrawal of 5 mL of concentrate (equivalent to 4 mg zoledronic acid)
  • This concentrate should immediately be diluted in 100 mL of sterile 0.9% Sodium Chloride, USP, or 5% Dextrose Injection, USP following proper aseptic technique, and administered to the patient by infusion
  • Do not store undiluted concentrate in a syringe, to avoid inadvertent injection
  • If not used immediately after dilution with infusion media, for microbiological integrity, the solution should be refrigerated at 2°C-8°C (36°F-46°F)
  • Due to the risk of clinically significant deterioration in renal function, which may progress to renal failure, single doses of zoledronic acid injection should not exceed 4 mg and the duration of infusion should be no less than 15 minutes
  • Prolia® (denosumab) is indicated for the treatment of postmenopausal women with osteoporosis at high risk for fracture, defined as a history of osteoporotic fracture, or multiple risk factors for fracture; or patients who have failed or are intolerant to other available osteoporosis therapy
  • Prolia is indicated as a treatment to increase bone mass in men at high risk for fracture receiving androgen deprivation therapy for nonmetastatic prostate cancer
  • Prolia is indicated as a treatment to increase bone mass in women at high risk for fracture receiving adjuvant aromatase inhibitor therapy for breast cancer
  • All patients should receive calcium 1000 mg daily and at least 400 IU vitamin D daily
  • Pre-existing hypocalcemia must be corrected prior to initiating Prolia®
  • Administer 60 mg every 6 months as a subcutaneous injection in the upper arm, upper thigh, or abdomen
  • Each 1 mL single-use prefilled syringe of Prolia contains 60 mg denosumab (60 mg/mL solution), 4.7% sorbitol, 17 mM acetate, 0.01% polysorbate 20, Water for Injection (USP), and sodium hydroxide to a pH of 5.2
  • Store Prolia in a refrigerator at 2°C to 8°C (36°F to 46°F) in the original carton
  • Protect Prolia from direct light and heat